SM-4300, a newly developed human immunoglobulin for intravenous use, has been studied for the safety and effectiveness/efficacy in the 7 patients with severe respiratory infections and a patient with fever of undetermined origin. Severe infections in the patients considered of 3 cases of pneumonia, 2 of obstructive pneumonia due to lung cancer, 2 of diffuse panbronchiolitis and 1 of fever of undetermined origin. Clinical effects of SM-4300 were excellent in 1 case, good in 1, fair in 2 and poor in 4. The efficacy rate was 25.0%. The appearance of subjective and objective clinical side effects and abnormal laboratory findings related to SM-4300 administration were not noted.